Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PNLIP | P16233 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SCN4A | P35499 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13715381 | 0.85 | HSPB1 (0.47) | HSPB1LMNAMAPK14PNLIPSCN4A | |
| SCHEMBL1151008 | 0.81 | SLC6A4 (0.47) | LMNANPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL9480232 | 0.81 | KDM4E (0.47) | LMNAGAATDP1CYP1A2CYP2C19 | |
| SCHEMBL13715246 | 0.81 | PLA2G2A (0.41) | HSPB1LMNAMAPK14SCN8ASCN10A | |
| SCHEMBL4851442 | 0.80 | TDP1 (0.65) | HSPB1LMNATDP1 | |
| SCHEMBL13715197 | 0.79 | PLA2G2A (0.40) | HSPB1LMNAMAPK14SCN8ASCN10A | |
| SCHEMBL15669422 | 0.79 | NPC1 (0.53) | HSPB1LMNANPC1GAARAB9A | |
| SCHEMBL13715276 | 0.77 | FFAR4 (0.39) | HSPB1LMNAMAPK14SCN8ASCN10A | |
| SCHEMBL11860422 | 0.76 | SLC6A3 (0.55) | LMNANPC1RAB9ASMN1; SMN2PNLIP | |
| SCHEMBL3888953 | 0.76 | POLB (0.38) | HSPB1LMNAMAPK14SCN8ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572783-B2 | Obesity; N-(1-benzyl-piperidin-4-yl)-2-(2,5-dioxo-7-phenoxy-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)-3-methyl-butyramide; modulators of ghrelin receptor (GHSR) | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572783-B2 | Obesity; N-(1-benzyl-piperidin-4-yl)-2-(2,5-dioxo-7-phenoxy-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)-3-methyl-butyramide; modulators of ghrelin receptor (GHSR) | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572783-B2 | Obesity; N-(1-benzyl-piperidin-4-yl)-2-(2,5-dioxo-7-phenoxy-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)-3-methyl-butyramide; modulators of ghrelin receptor (GHSR) | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20060199796-A1 | Substituted benzofused heterocycles | AMGEN INC. (US) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199796-A1 | Substituted benzofused heterocycles | GPR119, SDHA, OGDH | HSPB1 3323/4885LMNA 3352/4885MAPK14 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.